SOLICITATION NOTICE
B -- Genomics DNA Services
- Notice Date
- 6/7/2011
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HL)-2011-193-DDC
- Archive Date
- 6/28/2011
- Point of Contact
- Deborah - Coulter, Phone: (301) 435-0368
- E-Mail Address
-
dc143b@nih.gov
(dc143b@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The COAC Services Branch, Office of Acquisitions, DERA, National Heart, Lung, and Blood Institute (NHLBI), NIH, for the Framingham Heart Study under the NHLBI, Division of Intramural Research (DIR) Center for Population Studies, intends to award a purchase order on a sole source basis for the purchase of Genomics DNA Services from Beckman Coulter Genomics. The reference number: NHLBI-CSB-(HL)-2011-193-DDC. Background: Cardiovascular disease (CVD) is the leading cause of death and serious illness in the United States. In 1948, the Framingham Heart Study -- under the direction of the National Heart Institute (now known as the National Heart, Lung, and Blood Institute; NHLBI) -- embarked on an ambitious project in health research. At the time, little was known about the general causes of heart disease and stroke, but the death rates for CVD had been increasing steadily since the beginning of the century and had become an American epidemic. The objective of the Framingham Heart Study was to identify the common factors or characteristics that contribute to CVD by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke. The Framingham Heart Study continues to make important scientific contributions by enhancing its research capabilities and capitalizing on its inherent resources. Purpose: The Government has recently completed urinary biomarker profiles in 2900 participants from the Framingham Heart Study. The Framingham facility has used the genome-wide association studies (GWAS) and identified a strong association between a SNP in the LRP2 gene and trefoil-3, a urinary biomarker that is associated with GFR and CKD. In subsequent work, the lab showed that this SNP is also associated with variation in eGFR in the CKDGen consortium. The Framingham Heart Study, now wish to sequence the LRP2 gene among individuals with extreme high and low levels of trefoil-3 in order to uncover rare genetic variants that might be associated with CKD. The Government hypothesize that these rare variants will also be associated with CKD. This project involves the sequencing of the LRP2 gene in 200 samples from the Framingham Heart Study, and promptly returning the data within 8 weeks to The Framingham Heart Study. Period of Performance: June 15, 2011 through December 14, 2011. Contractor Requirements: A. Contractor will provide sequencing services to sequence 200 individuals at the LRP2 gene. The contractor will process NHLBI samples at contractor location using Sanger sequencing methods. B. The Contractor will provide high quality assay results C. Quality control measures will be applied by the Contractor and assay results will be accompanied by quality control information reflecting SNP QC. D. Contractor will specify any special packaging, marking, or shipping instructions for sample shipment. E. Each sample received will be identified by the Contractor using the identifiers provided by NHLBI. Government Responsibilities: A. NHLBI will provide to the Contractor 4 ug of DNA per SNP per person. In addition, NHLBI will provide a list of identifiers for the sequencing samples. Reporting Requirements and Deliverables: A. Sequencing results will be returned by Contractor to NHLBI in a standard format in a nonproprietary database in which the sequence data is identified by a standard name. B. Return of the sequence data by the Contractor will be accompanied by summary quality control measures. C. Sequence data will be returned to NHLBI within 8 weeks of receipt of the DNA samples. Program Management and Control Requirements: No special management or control systems are required under this contract. Type of service to be purchased: 1. Assay Design and Validation, quantity 72 each 2. PCR Setup and Sequencing, quantity 72 each 3. SNP and Indel Verification (Manual Review), quantity 72 each The sole source determination is based on the fact the National Institute of Health (NIH) is the nation's medical research agency and the primary Federal agency conducting and supporting making medical discoveries that improve people's health and save lives. The Framingham SABRe CVD Initiative Study under the National Heart, Lung, and Blood Institute (NHLBI) of NIH is conducting a study to identify the common factors or characteristics that contribute to Cardiovascular Disease (CVD) by following the development over a long period of time in a large group of participants who have not yet developed overt symptoms of CVD or suffered a heart attack or stroke. Chronic kidney disease is an important risk factor for cardiovascular disease, and many risk factors for chronic kidney disease are also risk factors for cardiovascular disease. As such, a major goal of the lab is to understand predictors of chronic kidney disease, with a particular focus on the genetic determinants of kidney disease. Genome-wide association has been performed to great success, and has identified common genetic variants in association with chronic kidney disease. The next step is to identify rare variants in these genes that might explain larger degrees of trait variation. The method to discover rare variants involve sequencing; Sequencing of a region or gene, such as the LRP2 gene. In addition it is important to use standard techniques across projects. The Government previously used Beckman Coulter Genomics for a prior sequencing project of the UMOD gene; harmonization of methods is critically important in order to minimize technical differences in the approach. Therefore, it is in the Government's best interest to continue the service with Beckman Coulter Genomics for the purpose to fulfill this project as it relates to goal of the Government. The delivery point is the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Framingham Heart Study, 73 Mt. Watye Avenue Perini Building, Framingham MA 01702. The notice of intent is not a request for competitive proposals. Only one responsible source and no other supplies or services will satisfy agency requirements. Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology with size standard of 500 employees; the small business set-aside does not apply for this requirement. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001) and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-50 (May 16, 2011). This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by June 13, 2011, 7:30 am Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Inquires to this announcement, referencing synopsis number NHLBI-CSB-(HL)-2011-193-DDC, may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisition, Procurement Branch, 6701 Rockledge Drive, Suite 6042, Bethesda, Maryland 20892-7902, Attention: Deborah Coulter. Response may be submitted electronically to coulterd@nhlbi.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HL)-2011-193-DDC/listing.html)
- Place of Performance
- Address: Framingham Heart Study, Framingham, Massachusetts, 01702, United States
- Zip Code: 01702
- Zip Code: 01702
- Record
- SN02466341-W 20110609/110607235135-3b61f69de87feb81e9a6b5b0440eec34 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |